Athira Pharma Q1 net loss $21.0M; topline ACT-AD Phase 2 data by end of 2Q22

LeonaBio, Inc.

2023-Q1 EPS reported -$0.56

Net loss $21.0M ($0.56/share) vs $8.9M ($0.25/share) in Q1 2021; R&D expense $14.5M, up from $7.4M.
Cash, equivalents & investments $301.2M at March 31, 2022 vs $319.7M at December 31, 2021.
Topline ACT-AD Phase 2 data in mild-to-moderate Alzheimer's expected by end of Q2 2022.
LIFT-AD Phase 3 enrollment target increased to ~420 patients; completion expected in Q3 2022.
Dosed first patient in SHAPE Phase 2 trial for Parkinson's disease dementia and Dementia with Lewy bodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.